Humasis Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 52.35%

Humasis Co. Ltd (205470) has an Asset Resilience Ratio of 52.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 205470 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩177.84 Billion
≈ $120.52 Million USD Cash + Short-term Investments

Total Assets

₩339.69 Billion
≈ $230.21 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Humasis Co. Ltd's Asset Resilience Ratio has changed over time. See 205470 equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Humasis Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Humasis Co. Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩177.84 Billion 52.35%
Total Liquid Assets ₩177.84 Billion 52.35%

Asset Resilience Insights

  • Very High Liquidity: Humasis Co. Ltd maintains exceptional liquid asset reserves at 52.35% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Humasis Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Humasis Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Cochlear Ltd
AU:COH
Medical Devices 9.76%
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 39.15%
HOB Biotech Group Corp Ltd
SHG:688656
Medical Devices 2.62%
Polynovo Ltd
AU:PNV
Medical Devices 0.04%
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
Medical Devices 10.88%
Dirui Industrial Co Ltd
SHE:300396
Medical Devices 6.89%
Emvision Medical Devices Ltd
AU:EMV
Medical Devices 0.06%

Annual Asset Resilience Ratio for Humasis Co. Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Humasis Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 58.65% ₩194.68 Billion
≈ $131.93 Million
₩331.92 Billion
≈ $224.93 Million
-11.31pp
2023-12-31 69.96% ₩242.99 Billion
≈ $164.67 Million
₩347.31 Billion
≈ $235.37 Million
+1.80pp
2022-12-31 68.16% ₩318.69 Billion
≈ $215.97 Million
₩467.53 Billion
≈ $316.84 Million
+10.88pp
2021-12-31 57.29% ₩195.19 Billion
≈ $132.28 Million
₩340.71 Billion
≈ $230.90 Million
+23.65pp
2020-12-31 33.64% ₩22.99 Billion
≈ $15.58 Million
₩68.35 Billion
≈ $46.32 Million
-25.57pp
2019-12-31 59.21% ₩21.60 Billion
≈ $14.64 Million
₩36.49 Billion
≈ $24.73 Million
-1.64pp
2018-12-31 60.85% ₩20.87 Billion
≈ $14.14 Million
₩34.29 Billion
≈ $23.24 Million
+6.10pp
2017-12-31 54.75% ₩15.51 Billion
≈ $10.51 Million
₩28.32 Billion
≈ $19.19 Million
-45.03pp
2016-12-31 99.78% ₩12.10 Billion
≈ $8.20 Million
₩12.13 Billion
≈ $8.22 Million
--
pp = percentage points

About Humasis Co. Ltd

KQ:205470 Korea Medical Devices
Market Cap
$214.71 Million
₩316.83 Billion KRW
Market Cap Rank
#16375 Global
#606 in Korea
Share Price
₩2800.00
Change (1 day)
+0.90%
52-Week Range
₩682.00 - ₩4265.00
All Time High
₩8520.77
About

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more